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ABSTRACT
Background and the purpose of the study: The relative in vivo bioavailability and in vitro 
dissolution  studies  of  three  chemically  equivalent  amiodarone  generic  products  in  healthy 
volunteers was evaluated in three separate occasions. The possibility of a correlation between in 
vitro and in vivo performances of these tablet formulations was also evaluated. 
Methods: The bioequivalence studies were conducted based on a single dose, two-sequence, 
cross over randomized design. The bioavailability was compared using AUC0-72, AUC0-∞, Cmax 
and Tmax. Similarity factor, dissolution efficiency (DE), and mean dissolution time (MDT) was 
used to compare the dissolution profiles. Polynomial linear correlation models were tested using 
either MDT vs mean residence time (MRT) or fraction of the drug dissolved (FRD) vs fraction 
of the drug absorbed (FRA). 
Results:  Significant  differences  were  found  in  the  dissolution  performances  of  the  tested 
formulations and therefore they were included in the development of the correlation. The 90% 
confidence intervals of the log-transformed AUC0-72, AUC0-∞, and Cmax of each two formulations 
in each bioequivalence studies were within the acceptable range of 80-125%. Differences were 
not observed between the untransformed Tmax values. Poor correlation was found between 
MRT and MDT of the products. A point-to-point correlation which is essential for a reliable 
correlation was not obtained between pooled FRD and FRA. The dissolution condition which 
was used for amiodarone tablets failed for formulations which were bioequivalent in vivo and 
significant difference between the dissolution characteristics of products (f2<50) did not reflect 
their in vivo properties. 
Major conclusions: Bioequivalence studies should be considered as the only acceptable way to 
ensure the interchangeability and in vivo equivalence of amiodarone generic drug products. The 
dissolution conditions used of the present study could be used for routine and in-process quality 
control of amiodarone tablet formulations. 
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INTRODUCTION
Amiodarone, [2-butyl-3-(3,5-diiodo-4-β-diethyl- 
aminoethoxybenzoyl) benzofuran], initially used as an 
antianginal (1), is now widely used in the management 
of severe ventricular and supraventricular arrhythmias 
(2). It belongs to the class III anti-arrhythmic drugs, 
which prolong the duration of the action potential 
and the effective refractory period in both atria and 
ventricles (2). Amiodarone is absorbed variably 
and erratically from the gastrointestinal tract. Oral 
bioavailability ranges from 22 to 86% (3, 4). The low 
solubility  of  amiodarone  in  aqueous  solution  and 
hepatic first pass effect which has not been clearly 
defined  might  be  a  reason  for  its  unpredictable 
absorption (5, 6). Amiodarone belongs to class II 
biopharmaceutical classification system (BCS) which 
is characterized by high membrane permeability and 
slow dissolution rate due to low aqueous solubility 
(7). 
Certain changes  in the formulation, the manufacturing 
process, the site of manufacture and the scale-up of 
the manufacturing process may alter the dissolution 
rate  and  the  bioavailability  of  drug  from  solid 
dosage  forms.  Therefore,  bioavailability  issues 
have been of increasing concern to drug regulatory 
authorities for assessment of the safety and efficacy 
of drug products. Local drug regulatory authorities 
have, therefore, issued guidelines to ensure adequate 
bioavailability studies in new drug applications for 
synonym drugs (8). 
While  the  pharmacokinetics,  metabolism,  and 
bioavailability  of  amiodarone  have  been  studied 
(2-6), the bioequivalence of the marketed products 
has not been described and no information about 
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Drug content uniformity in tablet formulations 
From each formulation, 20 tablets were transferred 
into  a  50-ml  volumetric  flask  containing  25  ml 
of  methanol,  sonicated,  diluted  with  methanol  to 
volume, mixed and filtered. Samples were assayed 
by  a  HPLC  method  developed  in  this  laboratory. 
Briefly, an aliquot of 25 μl of clear sample solution 
was  analyzed  on  a  μ-bondapack  C18  (150  ×  4.6 
mm) column, using acetonitrile-methanol (1:1) and 
0.05  M  monobasic  potassium  phosphate  solution 
in  deionized  water  (90:10,  final  pH,  3.5)  at  243 
nm. Drug contents of samples were determined by 
calibration curve.
Dissolution studies
The  release  characteristics  of  tested  formulations 
were determined using USP Apparatus II (Pharma 
Test, PTZWS3, Germany) at 75 rpm in 900 ml of 
acetate buffer (pH = 5, 0.1 M) containing 1% SLS 
maintained  at  37  ±  0.2°C.  Dissolution  tests  were 
performed on 12 tablets  at time intervals of 0, 5, 
10, 15, 30, 45, 60, 75, 90, 105, and 120 minutes 
using,  5  ml  samples.  Samples  were  filtered  and 
analyzed  spectrophotometrically  for  amiodarone 
concentration in order to characterize the dissolution 
profiles.
Bioavailability studies
Three separate bioequivalence studies (study 1, 2, 
and 3) on three commercial generic products (T1, 
T2, and T3) were conducted during 2000 - 2005. 
For each study, twelve healthy adult male volunteers 
were recruited. Age (years), weight (kg) and height 
(cm) of participants in the study 1 were 22-26, 59-
79, and 168-192, for the study 2 were  20-27, 65-90, 
165-184 and for the study 3, were 19-25, 62-87, 165-
185, respectively. The studies were approved by the 
ethics committee on human studies of the Isfahan 
University  of  Medical  Sciences.  On  the  basis  of 
medical history, clinical examinations and laboratory 
tests,  no  subject  had  a  history  and  evidence  of 
hepatic,  renal,  gastro-intestinal  or  hematological 
disorders or any acute or chronic disease or drug 
allergy.  The  subjects  were  instructed  to  abstain 
from taking any medication at least 2 weeks prior 
to and during the study period. Informed consent 
was  obtained  from  the  subjects  after  explaining 
the nature and purpose of the study. The protocol 
was the conventional, randomized, two-way cross-
over bioequivalence study with twelve subjects in 
each treatment group. In the first trial period, after 
an overnight fasting, subjects were given a single 
dose of either formulation (reference or test) in a 
randomized fashion with 200 ml of water. Food and 
drinks (other than water, which was allowed after 
2 hrs) were not allowed for 4 hrs after dosing to all 
volunteers. Approximately 10 ml of blood samples 
were drawn into tubes through an indwelling canola 
in vitro-in vivo correlation (IVIVC) of this drug is 
available. 
One of the challenges of biopharmaceutics research 
is correlation of the in vitro drug release information 
of  various  drug  formulations  to  the  in  vivo  drug 
profiles (9). For amiodarone, a correlation between 
dissolution rate and the in vivo performance might 
be expected (8-10). 
Since drug release pattern from each dosage form 
is significantly affected by the special design which 
is employed in manufacturing of the formulations, 
planning an in vitro dissolution method corresponding 
to the in vivo drug absorption rate, will facilitate the 
development of the drug formulations and quality 
control tests (9-11). For the development of an ideal 
oral formulation of amiodarone, it would be highly 
desirable to have an appropriate dissolution method 
which could predict the progress of the drug release 
and the in vivo release rate of the drug. An official 
monograph of amiodarone tablet formulation does 
not  exist  in  any  accredited  pharmacopoeia  and 
appropriate  dissolution  conditions  have  not  yet 
been described for this drug. However, a dissolution 
method for amiodarone tablet is recently proposed 
by  FDA.  Therefore,  an  appropriate  dissolution 
conditions based on in vivo performance could be 
more confidently adapted for routine and in-process 
quality control studies. 
This paper describes the result of the bioequivalence 
study and dissolution behavior of six (three reference 
and  three  test  tablet  formulations)  immediate 
release  amiodarone  tablet  formulations.  Since  the 
in vitro dissolution characteristics of these tablets 
exhibited different release pattern, the possibility of 
correlation between in vitro dissolution data and in 
vivo bioavailability of these tablet formulations was 
also investigated. 
MATERIAL  AND METHODS
Materials
Products  under  the  study  were  six  amiodarone 
immediate-release  tablet  formulations  containing 
200 mg amiodarone hydrochloride which exhibited 
different release pattern due to variation in proprietary 
manufacturing procedure. For tests T1, T2, T3 and 
for  References  R1,  R2,  and  R3  were  designated 
for  identification. Amiodarone  hydrochloride  was 
obtained  from  Sigma  (St.  Louis,  MO,  USA), 
the  internal  standard,  trifluoperazine  was  from 
SmithKline Beecham Inc. (Philadelphia, PA, USA), 
hydrochloric  acid,  tribasic  sodium  phosphate, 
monobasic sodium phosphate, orthophosphoric acid 
85%,  sodium  laurylsulphate,  ammonium  acetate, 
sodium acetate, acetonitrile, and hexane, were from 
Merck (Germany), methanol and acetonitrile were 
from Caledon (Canada, Ontario). All reagents and 
solutions of this study were analytical grade except 
methanol and acetonitrile which were HPLC grade.195
before (0 h) and at 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 
48, 60 and 72 hrs after dosing. The blood samples 
were centrifuged at 3000 rpm for 15 min and serum 
samples were separated and kept frozen at -200C in 
coded glass tubes until analysis.
 
HPLC assay
A  reversed  phase  HPLC  method  was  developed 
in home to quantitate serum levels of amiodarone. 
Chromatographic separation was performed using a 
μ-Bondapak C18 (250 × 3.9 mm, Waters, Ireland) 
column. The mobile phase consisted of acetonitrile- 
0.01 M KH2PO4 solution (70/30) containing 20 μl 
triethylamine with the final pH of 4.0. The aqueous 
phase was eluted at a flow rate of 1.5 ml/min and 
effluent  was  monitored  at  243  nm.  To  1  ml  of   
either  blank  serum  spiked  with  different  amount 
of  amiodarone  (calibration  samples)  or  serum  of 
volunteers in a 10 ml test tube, were added 50 µl 
of  internal  standard  solution,  trifluoperazine,  1  ml 
of sodium acetate buffer (1 M, pH = 5.4), and 8 ml 
of hexane and vortexed and centrifuged at 2000 
g  for  3  min.  The  supernatant  was  separated  and 
evaporated  to  dryness  under  nitrogen  gas.  The 
residue  was  reconstituted  with  100  µl  of  mobile 
phase and 50 µl aliquot was injected into the HPLC 
column. The standard curve covering 10-500 ng/ml 
concentration range was linear, the inter- and intra-
day  precision  and  accuracy  were  less  than  10%, 
the limit of quantification was 10 ng/ml, and the 
extraction efficiency was between 92% to 95% for 
calibration standard concentrations. 
Dissolution data analyses
The in vitro drug release profiles of each two dosage 
forms (test versus reference) were compared using 
the similarity factor, f2, as described in FDA guidance 
for dissolution testing (13). Dissolution efficiency 
(DE) was used for comparison of dissolution rates 
and calculated as explained previously (12).
Mean  dissolution  time  (MDT)  was  considered  as 
a  basis  for  the  dissolution  rates  and  was  used  to 
establish the correlation with in vivo mean residence 
time (MRT). 
MDT was estimated by moment analysis as applied 
previously to tablet formulations (14). Dissolution 
rate constants (Kd) were calculated, assuming first 
order kinetics for fast dissolution products (r2 ranging 
0.942-0.986), from the slope of natural logarithm of 
the remaining percentage to be released versus time 
(15). The time at which the dissolution process was 
complete calculated from 0.693/Kd.
Pharmacokinetic analyses
The  pharmacokinetic  parameters  were  calculated 
by  non-compartmental  methods.  The  elimination 
rate constant (kE) was obtained from the least square 
fitted  terminal  log-linear  portion  of  the  plasma 
concentration-time profile. The area under the curve 
to the last measurable concentration (AUC0-t) was 
estimated by the linear trapezoidal rule. The area 
under  the  curve  extrapolated  to  infinity  (AUC0-∞) 
was calculated by equation of AUC0-t + Ct / kE where 
Ct  is  the  last  measured  concentration.  The  peak 
plasma concentration (Cmax) and corresponding time 
to peak (tmax) were determined by inspection of the 
individual  drug  serum  concentration-time  profiles 
(8).
Statistical analyses 
For the purpose of bioequivalence analysis, AUC 0-t, 
AUC 0-∞, C max and Tmax were considered as primary 
variables. For each of parameters, by an analysis 
of  variance  (ANOVA)  procedure  for  cross-over 
design  the  values  obtained  for  the  two  products 
were determined to assess the effect of treatment 
(formulation), periods, sequences, and subjects on 
the parameters (16). A difference between two related 
parameters was considered statistically significant 
for a P value of less than 0.05. The 90% confidence 
intervals of the pharmacokinetic parameters of the 
two products were also estimated. The AUC and Cmax 
values  were  logarithmically  transformed  prior  to 
the analysis (17). Non-parametric Wilcoxon signed 
rank test for paired samples, was used to compare 
values of Tmax of the test over the reference products. 
The inter-subject variation of AUC 0-t, AUC 0-∞, and 
Cmax  parameters  was  estimated  by  calculation  of 
the respective coefficient of variation (CV) using 
the mean square error obtained from the ANOVA 
procedure. All statistical analyses were performed 
on untransformed data using SPSS 10. 
Correlation development 
The correlation was developed using the data of mean 
amiodarone serum concentration vs time following 
ingestion  of  six  formulations.  The  principles  of 
statistical moment analysis were utilized to assess 
the correlation. In this level of correlation, the in 
vitro MDT of the product was compared to in vivo 
MRT. MDT was calculated as pointed out earlier 
and MRT was calculated using equation described 
by  Gibaldi  and  Perrier  (18).  An  approach  based 
on cumulative fraction absorbed was also utilized 
to  achieve  an  IVIVC.  Prior  to  development  of 
the  IVIVC,  the  fraction  of  the  drug  dissolved 
(FRD)  was  determined  using  the  aforementioned 
dissolution testing methods. In addition, the fraction 
of absorbed amiodarone (FRA) of each formulation 
was estimated by the Wagner-Nelson method. The 
cumulative fraction of the absorbed drug absorbed 
at time t was calculated as follows:
                                                                   (1)
where, Ct is serum concentration at time t and KE is 
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where, Ct is serum concentration at time t and KE is elimination rate constant (18).  
Linear correlations between FRD and FRA were established for pooled mean data of 
formulations from following equation: 
ax y y    0           (2) 
where, y0 and Į represents the regression parameters, y is FRA, and x is FRD. For the 
model the F-test and r were determined. 
 
RESULTS AND DISCUSSIONS 
In vitro studies 
All  products  met  the  general  pharmaceutical  specifications  for  weight  variation, 
content assay and content uniformity assay.    
Fig. 1 shows the dissolution profiles of both reference and test tablet formulations 
which exhibited relatively immediate release behavior. The CV% associated with the 
dissolution data at each sampling time and for each formulation was less than 10%. In 
general, under the above described dissolution condition, test tablets had a higher 
dissolution rate than the reference formulations. This observation was supported by 
statistical analyses comparing the DE of test and reference tablets profiles at 45 min 
(p  <  0.05).  ANOVA  revealed  significant  differences  in  DE  values  for  all  tablet 
formulations  (P<0.05)  except  for  R1  versus  R3  (DE,  49.6  ±  2.4  vs  41.1  ±  3.6; 
P=0.226). Products T1 and T3 showed faster dissolution rates reflected in greater DE 
(82.6 ± 3.5 and 75.1 ± 1.4, respectively); while T2, R2 and R3 exhibited slower 
dissolution rates as indicated in lower DE (58.8 ± 2.5, 35.8 ± 2.6, and 41.1 ± 3.9, 
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elimination rate constant (18). 
Linear  correlations  between  FRD  and  FRA  were 
established  for  pooled  mean  data  of  formulations 
from following equation:
                             (2)
where, y0 and α represents the regression parameters, 
y is FRA, and x is FRD. For the model the F-test and 
r were determined.
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reference and test tablet formulations which exhibited 
relatively  immediate  release  behavior.  The  CV% 
associated with the dissolution data at each sampling 
time and for each formulation was less than 10%. 
In  general,  under  the  above  described  dissolution 
condition, test tablets had a higher dissolution rate 
than  the  reference  formulations.  This  observation 
was supported by statistical analyses comparing the 
DE of test and reference tablets profiles at 45 min 
(p < 0.05). ANOVA revealed significant differences 
in DE values for all tablet formulations (P < 0.05) 
except for R1 versus R3 (DE, 49.6 ± 2.4 vs 41.1 ± 
3.6; P = 0.226). Products T1 and T3 showed faster 
dissolution rates reflected in greater DE (82.6 ± 3.5 
and 75.1 ± 1.4, respectively); while T2, R2 and R3 
exhibited  slower  dissolution  rates  as  indicated  in 
lower DE (58.8 ± 2.5, 35.8 ± 2.6, and 41.1 ± 3.9, 
respectively). On the basis of dissolution efficiencies 
of the tested products, significant differences were 
found in their dissolution performances and therefore 
were included in the development of IVIVC.  
In vivo studies
The  concentration-time  profile  following  oral 
administration  of  each  of  the  two  amiodarone 
hydrochloride tablet preparations (test vs reference) 
are  depicted  in  figure  2 A,  B,  and  C. The  mean 
pharmacokinetic  parameters  for  the  brands 
of  amiodarone  hydrochloride  tablets  are  also 
summarized in table 1. 
The AUC0-72, AUC0-∞, Cmax, and Tmax, for each pair 
of  products  (test  vs  reference)  in  three  separate 
bioequivalence studies were not statistically different     
(P  >  0.05),  suggesting  that  the  serum  profiles 
generated  by  reference  tablets  were  comparable 
to  those  produced  by  the  test  product  (Table  1). 
Moreover,  90%  confidence  intervals  of  the  AUC0-72, 
AUC0-∞, Cmax of the two formulations in each set 
Prameters T1
Mean
 ± 
SD
R1 
Mean
±
 SD
CI90% P value  -Intra
Subject
CV%
T2
Mean
 ± 
SD
R2 
Mean
±
 SD
CI90% P value  -Intra
Subject
CV%
T3
Mean
 ± 
SD
R3
Mean
±
 SD
CI90% P value  -Intra
Subject
CV% 
C max
 (μg/ml)
329
 ± 
128
350
 ± 
112
0.909 
– 
1.041
0.548 9.8
342
 ± 
92
354
 ± 
85
0.963 
– 
1.020
0.753 5.2
311
 ± 
93
342
 ± 
118
0.931
– 
1.018
0.344 6.5
AUC 0 – 72 
(μg.h/ml) 
5588
 ± 
1854
5625
 ± 
1973
0.947
 –
 1.058
0.931 8.1
4934
 ± 
1433
4807
 ± 
1245
0.981
 –
 
1.046
0.391 5.7
4876
 ± 
1603
4645
 ± 
1836
0.982
 –
 1.070
0.324 6.7
AUC 0 - ∞
(μg.h/ml)
5811
 ±
1917
5833
 ±
2078
0.946
 – 
1.059
0.957 8.2
5291
 ±
1486
5100
 ±
1296
0.982
 – 
1.053
0.351 6.1
5043
 ±
 1631
4865
 ±
1847
0.973
 – 
1.065
0.508 6.51
T max
(hrs)
5.42
±
1.47
5.17
±
1.64
–  0.691 -
6.15
±
 0.55
6.08 
±
 0.76
- 0.739 -
7.00
±
 0.74
6.67
±
 0.89
- 0.465 -
Table 1. Pharmacokinetic parameters of the three bioequivalence studies performed on each of the two products of amiodarone tablets (test and reference) 
administered orally to 12 healthy volunteers.
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Fig.  1.  Profiles  of  mean  dissolution  rate  of  tablet  formulations  of  amiodarone 
(references and tests) performed in acetate buffer (pH = 5) containing 1% SLS at 75 
rpm employing USP apparatus paddle method. Results are expressed as mean ± SD (n 
=12) of % total amiodarone content. 
Figure 1. Profiles of mean dissolution rate of tablet formulations 
of amiodarone (references and tests) performed in acetate buffer 
(pH = 5) containing 1% SLS at 75 rpm employing USP apparatus 
paddle method. Results are expressed as mean ± SD (n =12) of % 
total amiodarone content.
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of  studies  were  found  to  be  within  the  relative 
bioavailability acceptable range of 80-125% (Table 
1).  Wilcoxon  signed  rank  test  did  not  show  any 
difference between the untransformed values of Tmax 
of the test compared to the reference products. The 
intra-subject CV for AUC0-72, AUC0-∞, Cmax appeared 
to be small. On the basis of the above analysis the 
test products could be considered bioequivalent with 
references.
In vitro – In vivo relationship
An  appropriate  dissolution  conditions  based  on 
in vivo performance could be adapted for routine 
and in-process quality control of amiodarone tablet 
formulations. It was of interest, therefore, to explore 
if condition of dissolution of this study, which is 
very similar to what is proposed by FDA, correlates 
with  serum  plasma  profiles  already  obtained  by 
performing bioavailability studies. 
Four correlation levels have been defined as Level 
A,  B,  C,  and  multiple-level  C  (9,  19).  Statistical 
moment  analysis  has  been  suggested  as  a  better 
parameter to examine IVIVC (9). In addition, a level 
B correlation uses all in vitro and in vivo data and 
was therefore employed between MRT and MDT. A 
poor correlation (p = 0.033) between MRT and the 
in vitro MDT for the six products was found in the 
present study (Figure 3). 
An approach based on FRA and FRD from the dosage 
forms was utilized to test a level A correlation. The 
last sampling time for in vitro dissolution was 120 
minutes and the in vivo time points of up to 18 hrs 
were included in to correlation. 
Finally, figure 4 was constructed by plotting FRD 
versus FRA pooled data of the six products to give 
the following equation.
                                               
A point-to-point correlation which is the cornerstone 
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An approach based on FRA and FRD from the dosage forms was utilized to test a 
level A correlation. The last sampling time for in vitro dissolution was 120 minutes 
and the in vivo time points of up to 18 hrs were included in to correlation.  
Finally, Fig. 4 was constructed by plotting FRD versus FRA pooled data of the six 
products to give the following equation. 
12 . 11 928 . 0    x y
A point-to-point correlation which is the cornerstone of an acceptable and reliable 
correlation was not achieved. In addition, using the pair-wise procedure based on 
similarity  factors  (f2)  which  is  a  model  independent  approach,  the  f2  values of
(25.4%),  (29.2%)  and  (25.5%)  were  calculated  for  studies,  numbers  1,2  and  3 
respectively. Profiles were considered similar, where f2 values lie between 50-100%. 
As f2 values were not in the acceptance range, the products were considered not 
equivalent  with  respect  to  their  in  vitro  release  characteristics  (Fig  1).  Since 
dissolution of the drug from the test products were faster than that of the reference 
formulations, values of similarity factor were smaller. In order to find out a predictive 
in vitro dissolution method both similarity factor of in vitro dissolution testing and 
regression  parameters  of  IVIVC  should  be  taken  into  account.  The  dissolution 
condition which was used for amiodarone tablet formulations in the present study 
failed for formulations that are bioequivalent in vivo. Also very significant difference 
was observed between the dissolution characteristics of R1 and T1 (f2 = 25.4%, DE of 
49.6 ±3.5 vs 82.6 ± 3.5; P < 0.05), R2 and T2 (f2 = 29.2%, DE of 35.7 ± 2.6 vs 58.8 ± 
2.5; P < 0.05) and R3 and T3 (f2 = 25.5%, DE of 41.1 ±3.9 vs 75.9 ± 2.1; P < 0.05). 
These products were bioequivalent in vivo as shown in table 2. It seems that the 
dissolution  medium  of  the  present  study  does  not  completely  simulate  GI  tract 
conditions. It is reported that biorelevant dissolution media could be used successfully 
to predict the in vivo performance of poorly water-soluble drugs. Strong correlations 
have been obtained with the poorly soluble drugs when of biorelevant dissolution 
medium is used (20). Although in most cases the in vivo differences amongst MRT of 
the  various  formulations  were  statistically  significant,  they  were  not  considerably 
significant to yield a strong correlation between MRT and MDT. Further studies are 
suggested  with  conventional  and  more  sustained-release  formulations  using 
biorelevant dissolution medium. At a dose of 200 mg amiodarone HCl and aqueous 
solubility  of  0.5  mg/ml,  400  ml  of  fluid  are  required  to  dissolve  one  dose  of 
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Fig. 2. The mean serum amiodarone levels vs time profiles following ingestion of a 
single dose of the test and reference tablet products to 12 healthy volunteers. Data is 
shown  as  mean  ±  SD.  A:  bioequivalence  study  1,  B:  bioequivalence  study  2,  C: 
bioequivalence study 3. 
Fig. 3. Correlation between the mean dissolution time (MDT) (calculated from in 
vitro dissolution data) and mean residence time (MRT) (calculated from serum drug 
concentration  data).  Data  represent  the  mean  of  twelve  determinations  standard 
deviation.
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Figure 3. Correlation between the mean dissolution time (MDT) 
(calculated from in vitro dissolution data) and mean residence 
time (MRT) (calculated from serum drug concentration data). Data 
represent the mean of twelve determinations standard deviation.
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of  an  acceptable  and  reliable  correlation  was  not 
achieved. In addition, using the pair-wise procedure 
based on similarity factors (f2) which is a model 
independent  approach,  the  f2  values  of  (25.4%), 
(29.2%)  and  (25.5%)  were  calculated  for  studies, 
numbers  1,  2  and  3  respectively.  Profiles  were 
considered  similar,  where  f2  values  lie  between 
50-100%. As f2 values were not in the acceptance 
range, the products were considered not equivalent 
with respect to their in vitro release characteristics 
(Figure 1). Since dissolution of the drug from the 
test products were faster than that of the reference 
formulations, values of similarity factor were smaller. 
In order to find out a predictive in vitro dissolution 
method both similarity factor of in vitro dissolution 
testing and regression parameters of IVIVC should 
be  taken  into  account.  The  dissolution  condition 
which was used for amiodarone tablet formulations 
in the present study failed for formulations that are 
bioequivalent in vivo. Also very significant difference 
16
Fig. 4. In vitro-in vivo correlation between the fraction dissolved in vitro (FRD) and 
the  cumulative  fraction  absorbed  in  vivo  (FRA)  for  the  conventional  amiodarone 
tablet  formulations  under  study.  Each  point  represents  the  mean  of  twelve 
determinations. 
was observed between the dissolution characteristics 
of R1 and T1 (f2 = 25.4%, DE of 49.6 ±3.5 vs 82.6 
± 3.5; P < 0.05), R2 and T2 (f2 = 29.2%, DE of 35.7 
± 2.6 vs 58.8 ± 2.5; P < 0.05) and R3 and T3 (f2 = 
25.5%, DE of 41.1 ±3.9 vs 75.9 ± 2.1; P < 0.05). 
These products were bioequivalent in vivo as shown 
in table 1. It seems that the dissolution medium of the 
present study does not completely simulate GI tract 
conditions. It is reported that biorelevant dissolution 
media could be used successfully to predict the in 
vivo  performance  of  poorly  water-soluble  drugs. 
Strong  correlations  have  been  obtained  with  the 
poorly soluble drugs when of biorelevant dissolution 
medium is used (20). Although in most cases the 
in  vivo  differences  amongst  MRT  of  the  various 
formulations  were  statistically  significant,  they 
were not considerably significant to yield a strong 
correlation between MRT and MDT. Further studies 
are suggested with conventional and more sustained-
release  formulations  using  biorelevant  dissolution 
medium. At a dose of 200 mg amiodarone HCl and 
aqueous solubility of 0.5 mg/ml, 400 ml of fluid 
are  required  to  dissolve  one  dose  of  amiodarone 
HCl which results in a dosing number (Do) of 1.6 
(10). Therefore, the volume of water which is taken 
initially with the dosage form will dissolve the drug 
to a great extent and reduces the dependency of 
drug absorption to the drug dissolution. This may 
result in a poor correlation which was obtained in 
this study.   
CONCLUSION
From  the  results  of  the  present  study,  it  may  be 
concluded  that  bioequivalence  studies  should  be 
conducted as the only acceptable means to ensure 
the  interchangeability  and  in  vivo  equivalence  of 
amiodarone generic drug products. The dissolution 
condition  of  the  present  study  could  be  used  for 
routine and in-process quality control of amiodarone 
tablet formulations. 
Figure 4. In vitro-in vivo correlation between the fraction dissolved 
in vitro (FRD) and the cumulative fraction absorbed in vivo (FRA) 
for the conventional amiodarone tablet formulations under study. 
Each point represents the mean of twelve determinations. 
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